Invesco Exchange-Traded Fund Trust Invesco RAFI US 1500 Small-Mid ETF (PRFZ) is a publicly traded the market company. As of May 21, 2026, PRFZ trades at $49.31 with a market cap of $0 and a P/E ratio of 0.00. PRFZ moved -0.30% today. Year to date, PRFZ is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces PRFZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Emergent BioSolutions Gains FDA Approval for 6-Count and 24-Count NARCAN Multipacks: Emergent BioSolutions won FDA approval for 6- and 24-pack NARCAN Nasal Spray, enabling expanded high-volume naloxone distribution and building on over 85 million doses shipped since 2016. With a 0.42% weight in Invesco RAFI US 1500 Small-Mid ETF, this approval may modestly boost the fund’s healthcare exposure.
| Metric | Value |
|---|---|
| Price | $49.31 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 110.71K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
PRFZ analyst coverage data. Average price target: $0.00.